{"transactions":[{"id":4616292,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-11T22:12:13.000Z","date":"2026-09-10","kind":"exercise","planned":true,"acquired":false,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 plan adopted on 3/13/2026 and modified on 6/11/2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of this option vested and became exercisable on October 10, 2020, with another 25% vesting on September 14, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":1638968,"derivative":{"exercise_price":1.55,"expiration_date":"2030-10-10","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001873905-26-000002","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1873905/000187390526000002/ownership.xml","form_type":"4"}},{"id":4616291,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-11T22:12:13.000Z","date":"2026-09-11","kind":"sale","planned":true,"acquired":false,"shares":59379,"price":10.4564,"value":620890.5756,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 plan adopted on 3/13/2026 and modified on 6/11/2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $11.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 herein."}],"balance_after":113321,"source":{"system":"sec-edgar","filing":"0001873905-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1873905/000187390526000002/ownership.xml","form_type":"4"}},{"id":4616290,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-11T22:12:13.000Z","date":"2026-09-10","kind":"sale","planned":true,"acquired":false,"shares":220866,"price":11.4997,"value":2539892.7402,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 plan adopted on 3/13/2026 and modified on 6/11/2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.20 to $12.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 herein."}],"balance_after":172700,"source":{"system":"sec-edgar","filing":"0001873905-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873905/000187390526000002/ownership.xml","form_type":"4"}},{"id":4616289,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-11T22:12:13.000Z","date":"2026-09-10","kind":"exercise","planned":true,"acquired":true,"shares":125000,"price":1.55,"value":193750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 plan adopted on 3/13/2026 and modified on 6/11/2026."}],"balance_after":393566,"source":{"system":"sec-edgar","filing":"0001873905-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873905/000187390526000002/ownership.xml","form_type":"4"}},{"id":928639,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-28T22:01:24.000Z","date":"2026-01-26","kind":"grant","planned":false,"acquired":true,"shares":629000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 26, 2026, subject to the Reporting Person's continued service on each vesting date."}],"balance_after":629000,"derivative":{"exercise_price":6.01,"expiration_date":"2036-01-26","underlying":"Common Stock","underlying_shares":629000},"source":{"system":"sec-edgar","filing":"0001193125-26-027396","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000119312526027396/ownership.xml","form_type":"4"}},{"id":1100770,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-06-26T12:30:12.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":42826,"price":4.67,"value":199997.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares acquired from the Issuer in a registered direct offering pursuant to the terms of a Securities Purchase Agreement dated as of June 23, 2025."}],"balance_after":268566,"source":{"system":"sec-edgar","filing":"0000950170-25-090198","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000095017025090198/ownership.xml","form_type":"4"}},{"id":1195364,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-20T20:35:42.000Z","date":"2025-03-19","kind":"sale","planned":true,"acquired":false,"shares":400,"price":9.0025,"value":3601.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/19/2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.00 to $9.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 herein."}],"balance_after":225740,"source":{"system":"sec-edgar","filing":"0000950170-25-042725","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000095017025042725/ownership.xml","form_type":"4"}},{"id":1195363,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-20T20:35:42.000Z","date":"2025-03-18","kind":"sale","planned":true,"acquired":false,"shares":25772,"price":8.7701,"value":226023.0172,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/19/2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.33 to $9.01, inclusive."}],"balance_after":226140,"source":{"system":"sec-edgar","filing":"0000950170-25-042725","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000095017025042725/ownership.xml","form_type":"4"}},{"id":1266540,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-14T21:30:05.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":525000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following February 12, 2025, subject to the Reporting Person's continued service on each vesting date."}],"balance_after":525000,"derivative":{"exercise_price":8.55,"expiration_date":"2035-02-12","underlying":"Common Stock","underlying_shares":525000},"source":{"system":"sec-edgar","filing":"0000950170-25-021283","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000095017025021283/ownership.xml","form_type":"4"}},{"id":1299552,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-01-17T21:30:05.000Z","date":"2025-01-15","kind":"sale","planned":false,"acquired":false,"shares":21704,"price":7.225,"value":156811.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units pursuant to the Issuer's mandatory sell to cover policy, which requires sales in an amount sufficient to cover tax withholding obligations associated with the vesting events, and the sales do not represent discretionary sales by the Reporting Person."}],"balance_after":251912,"source":{"system":"sec-edgar","filing":"0000950170-25-006724","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000095017025006724/ownership.xml","form_type":"4"}},{"id":1304804,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-01-10T21:30:08.000Z","date":"2025-01-08","kind":"sale","planned":false,"acquired":false,"shares":21172,"price":8.2182,"value":173995.7304,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units pursuant to the Issuer's mandatory sell to cover policy, which requires sales in an amount sufficient to cover tax withholding obligations associated with the vesting events, and the sales do not represent discretionary sales by the Reporting Person."}],"balance_after":273616,"source":{"system":"sec-edgar","filing":"0000950170-25-004198","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000095017025004198/ownership.xml","form_type":"4"}},{"id":1344160,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-12-03T22:48:05.000Z","date":"2024-11-29","kind":"sale","planned":false,"acquired":false,"shares":48847,"price":4.5556,"value":222527.3932,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units pursuant to the Issuer's mandatory sell to cover policy, which requires sales in an amount sufficient to cover tax withholding obligations associated with the vesting events, and the sales do not represent discretionary sales by the Reporting Person."}],"balance_after":294788,"source":{"system":"sec-edgar","filing":"0000950170-24-132930","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000095017024132930/ownership.xml","form_type":"4"}},{"id":1355483,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-21T20:07:23.000Z","date":"2024-11-21","kind":"exercise","planned":false,"acquired":false,"shares":12900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option vested and became exercisable on October 10, 2020, with another 25% vesting on October 10, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":1763968,"derivative":{"exercise_price":1.55,"expiration_date":"2030-10-10","underlying":"Common Stock","underlying_shares":12900},"source":{"system":"sec-edgar","filing":"0000950170-24-129677","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000095017024129677/ownership.xml","form_type":"4"}},{"id":1355482,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-11-21T20:07:23.000Z","date":"2024-11-21","kind":"exercise","planned":false,"acquired":true,"shares":12900,"price":1.55,"value":19995.0,"ownership":{"direct":true},"balance_after":343635,"source":{"system":"sec-edgar","filing":"0000950170-24-129677","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000095017024129677/ownership.xml","form_type":"4"}},{"id":1451016,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-07-19T12:29:42.000Z","date":"2024-07-17","kind":"sale","planned":false,"acquired":false,"shares":22528,"price":6.4726,"value":145814.7328,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units pursuant to the Issuer's mandatory sell to cover policy, which requires sales in an amount sufficient to cover tax withholding obligations associated with the vesting events, and the sales do not represent discretionary sales by the Reporting Person."}],"balance_after":330735,"source":{"system":"sec-edgar","filing":"0000950170-24-084761","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000095017024084761/ownership.xml","form_type":"4"}},{"id":1454374,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-07-15T12:35:22.000Z","date":"2024-07-11","kind":"sale","planned":false,"acquired":false,"shares":20293,"price":5.9734,"value":121218.2062,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units pursuant to the Issuer's mandatory sell to cover policy, which requires sales in an amount sufficient to cover tax withholding obligations associated with the vesting events, and the sales do not represent discretionary sales by the Reporting Person."}],"balance_after":353263,"source":{"system":"sec-edgar","filing":"0000950170-24-083401","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000095017024083401/ownership.xml","form_type":"4"}},{"id":1726389,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-11-30T22:00:17.000Z","date":"2023-11-28","kind":"tax_withholding","planned":false,"acquired":false,"shares":43443,"price":0.9,"value":39098.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were withheld by the Issuer to satisfy tax withholding obligations associated with the vesting and settlement of restricted stock units."}],"balance_after":373556,"source":{"system":"sec-edgar","filing":"0001209191-23-056987","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000120919123056987/doc4.xml","form_type":"4"}},{"id":1728259,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-11-28T21:30:36.000Z","date":"2023-11-26","kind":"grant","planned":false,"acquired":true,"shares":180108,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. 50% of the RSUs shall vest on June 30, 2024, and the remaining 50% on December 31, 2024, in each case subject to the Reporting Person's continued service on such vesting date."}],"balance_after":416999,"source":{"system":"sec-edgar","filing":"0001209191-23-056801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000120919123056801/doc4.xml","form_type":"4"}},{"id":1907782,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-02T21:10:18.000Z","date":"2023-04-28","kind":"grant","planned":false,"acquired":true,"shares":180000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One third of the shares underlying this option shall vest and become exercisable in forty-eight equal monthly installments following April 28, 2023, subject to the Reporting Person's continued service on each vesting date. One third of the shares underlying this option shall vest and become exercisable if the average closing market price of the Issuer's common stock exceeds $3.00 per share for at least 20 consecutive trading days prior to the expiration of the option. The final third of shares underlying this option shall vest and become exercisable if the average closing market price of the Issuer's common stock exceeds $4.50 per share for at least 20 consecutive trading days prior to the expiration of the option. If either stock price hurdle is achieved prior to April 28, 2024, the applicable award would vest fully on April 28, 2024, so long as the Reporting Person remains an employee or service provider of the Issuer through such date."}],"balance_after":180000,"derivative":{"exercise_price":1.29,"expiration_date":"2033-04-28","underlying":"Common Stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0001209191-23-026581","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000120919123026581/doc4.xml","form_type":"4"}},{"id":2089198,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-12T21:25:25.000Z","date":"2022-12-09","kind":"purchase","acquired":true,"shares":12935,"price":1.92,"value":24835.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.89 to $2.00. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":40985,"source":{"system":"sec-edgar","filing":"0001209191-22-060689","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000120919122060689/doc4.xml","form_type":"4"}},{"id":2089197,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-12T21:25:25.000Z","date":"2022-12-08","kind":"purchase","acquired":true,"shares":3050,"price":1.7,"value":5185.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.55 to $1.80. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":28050,"source":{"system":"sec-edgar","filing":"0001209191-22-060689","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000120919122060689/doc4.xml","form_type":"4"}},{"id":2101056,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-11-30T23:30:52.000Z","date":"2022-11-28","kind":"grant","acquired":true,"shares":195906,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. 50% of the RSUs shall vest on November 28, 2023, and the remaining 50% on November 28, 2024, in each case subject to the Reporting Person's continued service on such vesting date."}],"balance_after":220906,"source":{"system":"sec-edgar","filing":"0000899243-22-037231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000089924322037231/doc4.xml","form_type":"4"}},{"id":2364144,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-01T23:35:53.000Z","date":"2022-02-28","kind":"grant","acquired":true,"shares":330000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based and performance-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following the Grant Date, subject to the Reporting Person's continued service on each such vesting date; provided, however, that one-third of the shares underlying this option shall only become exercisable if the average market price of the Issuer's common stock equals or exceeds $13.50 for any ten consecutive trading days prior to or as of December 31, 2022, and an additional one-third of the shares underlying this option shall only become exercisable if the average market price of the Issuer's common stock equals or exceeds $20.00 for any ten consecutive trading days prior to or as of December 31, 2022."}],"balance_after":330000,"derivative":{"exercise_price":4.12,"expiration_date":"2032-02-28","underlying":"Common Stock","underlying_shares":330000},"source":{"system":"sec-edgar","filing":"0000899243-22-008373","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000089924322008373/doc4.xml","form_type":"4"}},{"id":2619606,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-08-03T00:09:09.000Z","date":"2021-07-29","kind":"purchase","acquired":true,"shares":25000,"price":8,"value":200000.0,"ownership":{"direct":true},"balance_after":25000,"source":{"system":"sec-edgar","filing":"0000899243-21-031097","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000089924321031097/doc4.xml","form_type":"4"}}]}